Cancer pain: From the development of mouse models to human clinical trials

Juan Miguel Jimenez Andrade, Patrick W Mantyh

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cancer-associated pain can be present at any time during the course of the disease, but the frequency and intensity of cancer pain tends to increase with advancing stages of cancer. In patients with advanced cancer, 62%–86% experience signicant pain, whichis described as moderate to severe in approximately 40%–50%and as very severe in 25%–30% (van den Beuken-van Everdingen et al. 2007). Bone cancer pain is the most common pain in patients with advanced cancer; two-thirds of patients with metastatic bone disease experience severe pain (Coleman 2006; Mercadante and Fulfaro 2007). Although bone is not a vital organ, many of the most common tumors (breast, prostate, thyroid, kidney, and lung) have a strong predilection for bone metastasis (Figure 4.1). Tumor metastases to the skeleton are major contributors to morbidity and mortality in metastatic cancer. Tumor growth in bone results in pain, hypercalcemia, anemia, increased susceptibility to infection, skeletal fractures.

Original languageEnglish (US)
Title of host publicationTranslational Pain Research
Subtitle of host publicationFrom Mouse to Man
PublisherCRC Press
Pages77-98
Number of pages22
ISBN (Electronic)9781439812105
ISBN (Print)9781138116047
StatePublished - Jan 1 2009

Fingerprint

Bone
Clinical Trials
Tumors
Pain
Neoplasms
Neoplasm Metastasis
Bone and Bones
Bone Neoplasms
Bone Diseases
Bone Development
Hypercalcemia
Skeleton
Cancer Pain
Anemia
Prostate
Thyroid Gland
Breast Neoplasms
Morbidity
Kidney
Lung

ASJC Scopus subject areas

  • Health Professions(all)
  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)

Cite this

Andrade, J. M. J., & Mantyh, P. W. (2009). Cancer pain: From the development of mouse models to human clinical trials. In Translational Pain Research: From Mouse to Man (pp. 77-98). CRC Press.

Cancer pain : From the development of mouse models to human clinical trials. / Andrade, Juan Miguel Jimenez; Mantyh, Patrick W.

Translational Pain Research: From Mouse to Man. CRC Press, 2009. p. 77-98.

Research output: Chapter in Book/Report/Conference proceedingChapter

Andrade, JMJ & Mantyh, PW 2009, Cancer pain: From the development of mouse models to human clinical trials. in Translational Pain Research: From Mouse to Man. CRC Press, pp. 77-98.
Andrade JMJ, Mantyh PW. Cancer pain: From the development of mouse models to human clinical trials. In Translational Pain Research: From Mouse to Man. CRC Press. 2009. p. 77-98
Andrade, Juan Miguel Jimenez ; Mantyh, Patrick W. / Cancer pain : From the development of mouse models to human clinical trials. Translational Pain Research: From Mouse to Man. CRC Press, 2009. pp. 77-98
@inbook{5da873cfaa15496abd3ee09b161365b5,
title = "Cancer pain: From the development of mouse models to human clinical trials",
abstract = "Cancer-associated pain can be present at any time during the course of the disease, but the frequency and intensity of cancer pain tends to increase with advancing stages of cancer. In patients with advanced cancer, 62{\%}–86{\%} experience signicant pain, whichis described as moderate to severe in approximately 40{\%}–50{\%}and as very severe in 25{\%}–30{\%} (van den Beuken-van Everdingen et al. 2007). Bone cancer pain is the most common pain in patients with advanced cancer; two-thirds of patients with metastatic bone disease experience severe pain (Coleman 2006; Mercadante and Fulfaro 2007). Although bone is not a vital organ, many of the most common tumors (breast, prostate, thyroid, kidney, and lung) have a strong predilection for bone metastasis (Figure 4.1). Tumor metastases to the skeleton are major contributors to morbidity and mortality in metastatic cancer. Tumor growth in bone results in pain, hypercalcemia, anemia, increased susceptibility to infection, skeletal fractures.",
author = "Andrade, {Juan Miguel Jimenez} and Mantyh, {Patrick W}",
year = "2009",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781138116047",
pages = "77--98",
booktitle = "Translational Pain Research",
publisher = "CRC Press",

}

TY - CHAP

T1 - Cancer pain

T2 - From the development of mouse models to human clinical trials

AU - Andrade, Juan Miguel Jimenez

AU - Mantyh, Patrick W

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Cancer-associated pain can be present at any time during the course of the disease, but the frequency and intensity of cancer pain tends to increase with advancing stages of cancer. In patients with advanced cancer, 62%–86% experience signicant pain, whichis described as moderate to severe in approximately 40%–50%and as very severe in 25%–30% (van den Beuken-van Everdingen et al. 2007). Bone cancer pain is the most common pain in patients with advanced cancer; two-thirds of patients with metastatic bone disease experience severe pain (Coleman 2006; Mercadante and Fulfaro 2007). Although bone is not a vital organ, many of the most common tumors (breast, prostate, thyroid, kidney, and lung) have a strong predilection for bone metastasis (Figure 4.1). Tumor metastases to the skeleton are major contributors to morbidity and mortality in metastatic cancer. Tumor growth in bone results in pain, hypercalcemia, anemia, increased susceptibility to infection, skeletal fractures.

AB - Cancer-associated pain can be present at any time during the course of the disease, but the frequency and intensity of cancer pain tends to increase with advancing stages of cancer. In patients with advanced cancer, 62%–86% experience signicant pain, whichis described as moderate to severe in approximately 40%–50%and as very severe in 25%–30% (van den Beuken-van Everdingen et al. 2007). Bone cancer pain is the most common pain in patients with advanced cancer; two-thirds of patients with metastatic bone disease experience severe pain (Coleman 2006; Mercadante and Fulfaro 2007). Although bone is not a vital organ, many of the most common tumors (breast, prostate, thyroid, kidney, and lung) have a strong predilection for bone metastasis (Figure 4.1). Tumor metastases to the skeleton are major contributors to morbidity and mortality in metastatic cancer. Tumor growth in bone results in pain, hypercalcemia, anemia, increased susceptibility to infection, skeletal fractures.

UR - http://www.scopus.com/inward/record.url?scp=85057656667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057656667&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85057656667

SN - 9781138116047

SP - 77

EP - 98

BT - Translational Pain Research

PB - CRC Press

ER -